Novartis Pharma AG: New data at ASH spotlight Novartis recently approved Scemblix, next-generation CAR-T platform and expanding hematology portfolio
New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies
Source: finanznachrichten.de